Clinical Trial Update: ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment [Phase 2]

View source ↗

Summary

A Phase 2 trial (ANNAPURNA) evaluated the combination of RO5466731, RO5190591, Ritonavir, and Ribavirin with or without RO5024048 in patients with Hepatitis C a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (Ribavirin) (ribavirin)
• RO5024048
• RO5190591
• RO5466731
• Ritonavir (Ritonavir)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED